ArticlePain management2025

Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol.

Damiana Scuteri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.